Genetically proxied ABCC8 inhibition showed strong evidence of association with decreased POAG risk using data from IGGC in the discovery stage with an OR of 0.152 (95% CI: 0.075–0.308; p < 0.001, per SD reduction in HbA1c). This evidence concerns the gene ABCC8 and open-angle glaucoma.